Parkinson disease (PD) is considered a sporadic neurodegenerative disorder, though genetic factors are frequently involved in its etiology. That some familial presentations of PD have been associated with different mutated genes suggests that some genetic variants can also modulate the risk for "nonfamilial" presentation of PD. The hypothesis-free genomewide association studies (GWAS) performed in PD and healthy controls 1,2 revealed that certain allele variants can increase the risk of sporadic PD. Replication studies are important, since they allow investigation of whether the risk loci found in the GWAS are also associated with PD in other populations, thus excluding spurious associations that could be a result, for instance, of an undetected population structure or from genotyping errors.
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In this issue of Neurology ® , Sharma and colleagues 3 report a replication study analyzing large PD and control samples in which they found associations of single nucleotide polymorphisms (SNPs) in 9 of the loci previously associated with PD. However, for 5 of the 9 replicated loci there was nominally significant between-site heterogeneity in the effect sizes. Their subgroup analysis by ethnicity, for example, showed stronger effects for BST1 in Asians than in Caucasians, but similar effects for SNCA, LRRK2, LAMP3, HIP1R, and STK39 in both populations, while MAPT and SYT11 SNPs analyzed were monomorphic in the Asian population, highlighting the role of population-specific heterogeneity in PD. These results suggest that the differences in both the associated genes as well as the degree of association found among studies and populations makes it difficult to interpret the exact individual risk due to these variants. [1] [2] [3] The sources of such heterogeneity, apart from ethnic differences, may have origin in the inclusion of other causes of parkinsonism or tremor, such as multiple system atrophy or essential tremor, in the patients' cohort. 4 One would guess that the PD misdiagnosis rate increases as the number of patients needed to detect any given association becomes larger. In addition, we know that PD can present with different clinical subtypes and severity. Thus, in improving patient characterization for GWAS studies, our efforts should be focused on the following: 1) avoiding non-PD "contamination" by recruiting subjects with PD for whom the diagnostic criteria as well as the clinical follow-up would reasonably discard clinical pathologies other than PD; and 2) differentiating specific subphenotypes/endophenotypes that can help to define more accurately the PD spectrum. In fact, we recently found that genetic variants in LINGO1, a gene recently associated with essential tremor, were particularly associated with the nonrigid-akinetic PD phenotype. 5 These results suggest that an effort to identify PD subtypes would improve accuracy in detecting more specific genetic disease risk variants, especially if focused on the search for (nongenetic) CSF or neuroimaging disease markers.
What is the value of knowing the susceptibility or protective genes in populations, and how does this translate to clinical practice? Since all the associated genetic loci increase the risk of PD slightly, no single common genetic variant gives a major risk. Theoretically, the sum of the odds ratios of the different loci would lead to an accurate prediction of the PD risk. Unfortunately, the results of the study by Sharma and colleagues 3 suggest that even the sum of the risk of several variants would not accurately predict the individual risk since there are still unknown genetic, clinical, or environmental PD risk factors.
What do the associated loci with PD tell us about PD? It is becoming clear that an association exists between loci located in or near parkinsonismlinked genes such as SNCA, MAPT, and LRRK2 genes, 1, 2, 6, 7 and new PD loci such as PARK16-18, BST1, and others. However, some of these loci can show a variable degree of association/replication in different populations. In addition, despite having strong evidence that these loci/genes are involved in PD risk, we still do not know for many of them whether the associated SNPs in such loci or other unknown variants in linkage disequilibrium with them are the causative disease-risk variants.
Among the loci associated with sporadic PD, 3 of them, SNCA, MAPT, and LRRK2, deserve special interest because of their role in neurodegenerative diseases. SNCA is the major component of Lewy bodies found in PD and SNCA locus triplication causes familial PD probably by increasing SNCA gene expression. 8 As SNCA alleles are associated with earlier disease onset, [8] [9] some SNCA variants may also modify PD risk by increasing the SNCA brain concentration.
The LRRK2 locus influences PD risk independently of the common G2019S LRRK2 PD mutation. Exhaustive LRRK2 sequencing of independent probands selected from PD families in which the affected persons shared LRRK2 haplotypes 10 found that only 1 of these families showed a novel pathogenic S1761R LRRK2 mutation, suggesting that unknown variants lying in LRRK2 regulatory regions or even in neighboring genes may be associated with PD.
Hyperphosphorylated MAPT brain aggregates are characteristic of the neurodegenerative disorders called tauopathies. The H1 MAPT haplotype is overrepresented not only in progressive supranuclear palsy and corticobasal degeneration, but also in PD, suggesting that unknown genetic risk variants for neurodegenerative disorders could lie in the extended H1 haplotype background. PD is not considered a classic tauopathy because of lack of brain MAPT inclusions, so the first report of the H1 MAPT genetic association with PD was unexpected. 7 PD association with 5Ј-MAPT SNPs suggests that genetic variability in this region could influence MAPT expression.
Hopefully, the use of next-generation sequencing technologies for analyzing such candidate regions will enable us to learn more about the variants responsible for risk of PD.
